The Board of Sareum notes recent speculation and confirms that it is in discussions with a party that may or may not lead to an offer being made for the Company.

A further announcement will be made when appropriate.

Enquiries:

Philip Secrett 0870 991 2578
Colin Aaronson 0870 991 2942

Grant Thornton Corporate Finance

  • @Sareumplc Latest tweet

    RT @RobinDavison2: Novel TYK2 inhibitor (BMS-986165) a ‘game changer’ for psoriasis... "almost 75% of the cohort reached PASI 75 response,… via @Sareumplc
    View more